Management of Immune Thrombocytopenic Purpura (ITP)

Diagnostic Approach

• Testing for HCV and HIV is recommended for all patients with suspected ITP (grade 1B) 1
• Bone marrow examination is not necessary for patients presenting with typical ITP (grade 2C) 1, 2
• Secondary causes of ITP should be ruled out, including antiphospholipid syndrome, autoimmune disorders, common variable immune deficiency, drug-induced thrombocytopenia, and infections 3, 4

First-Line Treatment Options

• First-line treatment for ITP should include corticosteroids, with the addition of IVIG when rapid platelet count increase is required 1, 2
• The American Society of Hematology recommends IVIG when a more rapid increase in platelet count is required (grade 2B) 1, 2
• Initial dose of IVIG should be 1 g/kg as a one-time dose; may be repeated if necessary 1

Second-Line Treatment Options

• Splenectomy is recommended for patients who have failed corticosteroid therapy (grade 1B) 3, 4
• Splenectomy provides long-term responses in 60-70% of patients 5
• Thrombopoietin Receptor Agonists (TPO-RAs) are recommended for patients at risk of bleeding who relapse after splenectomy or have contraindications to splenectomy and have failed at least one other therapy (grade 1B) 3, 4

Management of Secondary ITP

• Antiviral therapy should be considered in the absence of contraindications for HCV-associated ITP (grade 2C) 1, 3
• Treatment of HIV infection with antiviral therapy should be considered before other treatment options unless clinically significant bleeding is present (grade 1A) 1, 3
• Eradication therapy is recommended for patients who test positive for H. pylori (grade 1B) 1, 3

Special Populations

• Pregnant patients requiring treatment should receive either corticosteroids or IVIG (grade 1C) 1, 3
• Mode of delivery should be based on obstetric indications rather than platelet count (grade 2C) 1, 3